Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
AyuVis Research, Inc. is managing 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The prosecution is currently handled by 1 distinct examiner, which indicates a lack of diversity in the technical review groups for the pending portfolio. This concentration simplifies the tracking of office responses and examiner communications.
The busiest examiner for the company is CRAIGO, BAHAR ALAWI, who has the busiest examiner pending office action. This matter represents the full extent of the company's current pending interactions with the patent office. The focus on a single distinct art unit suggests the technology is being evaluated within a specific pharmaceutical classification.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CRAIGO, BAHAR ALAWI | 1 | 47.1% | +27.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17591280 | CHITIN ANALOGS FOR THE TREATMENT OF KIDNEY DISEASES | CRAIGO, BAHAR ALAWI | 11d overdue |
| Art Unit | Apps |
|---|---|
| 1699 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17591280 | CHITIN ANALOGS FOR THE TREATMENT OF KIDNEY DISEASES | CRAIGO, BAHAR ALAWI | 1699 | §103 | Non-Final OA | 11d overdue | Pending | Feb 02, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial